Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of multiple intravenous infusions of S95011
compared to placebo in reducing disease activity in patients with primary Sjögren's syndrome.